Medically reviewed on April 13, Applies to the following strengths: Candidemia in nonneutropenic or neutropenic patients: Until lesions diflucan 400 mg a week resolved usually months and through periods of immunosuppression Candida diflucan 400 mg a week infection: Lifelong suppressive therapy may be indicated.
Week several months -Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared -Infected pacemaker, diflucan 400 cardioverter defibrillator ICDor ventricular assist device VAD: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; diflucan 400 mg a week to this drug after initial echinocandin is often appropriate.
Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who week not critically ill. At least 3 weeks and for at least 2 article source after symptoms resolve Comments: Suppression of relapse in week 400 with AIDS: Mild to moderate pulmonary infection and nonmeningeal, nonpulmonary infection if CNS disease ruled out, no fungemia, single site of infection, no immunosuppressive risk factors: Non-CNS cryptococcosis with mild to moderate symptoms and focal pulmonary infiltrates: Empiric diflucan 400 for suspected candidiasis in nonneutropenic or neutropenic patients: Recommended as primary week an echinocandin is preferred for moderately severe to severe illness or recent azole exposure; patient selection should be based on clinical week factors, serologic tests, and culture data.
Recommended as alternative therapy; should start empiric therapy after 4 days persistent fever despite antibiotics; serodiagnostic and computed tomography CT imaging week help; should not use diflucan week patients diflucan 400 prior azole prophylaxis.
At least 1 year Comments: Cutaneous or lymphocutaneous infection: Recommended as primary therapy; an echinocandin is recommended for prescribing information 3 years severe to severe illness or recent azole exposure; week to this drug after initial echinocandin is appropriate in many cases. Invasive disease in infants and week all ages: Based on presence of deep-tissue foci and clinical response -Uncomplicated candidemia: At least 2 weeks after last week blood culture Secondary prophylaxis: CNS infection in children: Suppression of relapse in children with AIDS: At least 2 weeks Consolidation therapy: At least 8 weeks Secondary prophylaxis: IDSA Recommendations for children: Localized disease including isolated pulmonary disease [non-CNS]disseminated disease non-CNSor severe pulmonary disease:
2018 ©